Staphylococcus aureus/epidermidis vaccine - Nabi

Drug Profile

Staphylococcus aureus/epidermidis vaccine - Nabi

Latest Information Update: 23 May 2006

Price : $50

At a glance

  • Originator Nabi Biopharmaceuticals
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Staphylococcal infections

Most Recent Events

  • 23 May 2006 Discontinued - Preclinical for Staphylococcal infections in USA (unspecified route)
  • 12 Aug 2004 No development reported - Preclinical for Staphylococcal infections in USA (unspecified route)
  • 22 Mar 2002 Nabi is now called Nabi Biopharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top